Cholesterol Medicines — Medication Guide, Uses & Safety — Uses, Dosage & Side Effects | MyMedicPlus

Cholesterol medicines, also called lipid-lowering drugs or antilipemic agents, are prescription medications used to reduce elevated blood cholesterol and triglycerides — major modifiable risk factors for atherosclerosis, coronary artery disease, heart attack, and stroke. High LDL cholesterol drives the formation of fatty plaques (atherosclerosis) in arterial walls, which can rupture and cause myocardial infarction or ischemic stroke. Statins are the most prescribed first-line class for most patients, with extensive evidence supporting cardiovascular event reduction across a wide range of risk profiles. Other drug classes include ezetimibe (cholesterol absorption inhibitor), fibrates (fenofibrate, gemfibrozil — primarily for raised triglycerides), bile acid sequestrants (cholestyramine, colesevelam), niacin (extended-release — limited by side effects), and the newer injectable PCSK9 inhibitors (evolocumab, alirocumab) for patients with very high cardiovascular risk or statin intolerance requiring additional LDL lowering beyond what statins can provide. A novel RNA interference drug, inclisiran (Leqvio), administered by injection twice yearly, targets PCSK9 through a different mechanism. Cholesterol-lowering drugs are prescribed by cardiologists, general practitioners, and endocrinologists as part of a comprehensive cardiovascular risk reduction strategy.

Cholesterol-lowering medicines are prescribed for two main purposes: treating elevated blood cholesterol levels and reducing cardiovascular events. Statins are recommended for primary prevention (reducing the risk of a first cardiovascular event in people with elevated risk due to hypercholesterolemia, diabetes, hypertension, or multiple risk factors) and for secondary prevention (reducing the risk of recurrent events in people with established cardiovascular disease — heart attack, stroke, peripheral artery disease, coronary revascularization). Familial hypercholesterolemia (FH) — an inherited condition with very high LDL — requires intensive treatment beginning in childhood in some cases. Mixed dyslipidemia (elevated LDL and triglycerides with low HDL) may require combination therapy. Fibrates are primarily indicated for marked hypertriglyceridemia (triglycerides above 5.6 mmol/L or 500 mg/dL) due to the risk of pancreatitis. Ezetimibe is added to statin therapy when LDL remains above target. PCSK9 inhibitors are approved for adults with FH (including homozygous FH), or established cardiovascular disease requiring further LDL lowering on maximum statin therapy. Current treatment targets: LDL-C below 1.4 mmol/L (55 mg/dL) for very high cardiovascular risk; below 1.8 mmol/L (70 mg/dL) for high risk.

Each cholesterol-lowering drug class works through a different mechanism. Statins (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin) competitively inhibit HMG-CoA reductase — the rate-limiting enzyme in the liver's cholesterol synthesis pathway (mevalonate pathway). Reduced intrahepatic cholesterol production triggers upregulation of hepatic LDL receptors, which then clear more LDL particles from the bloodstream. Statins lower LDL-C by 30–55% depending on the specific statin and dose. Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in intestinal enterocytes, blocking dietary and biliary cholesterol absorption from the gut — lowering LDL by an additional 15–20% on top of statin therapy. Fibrates (fenofibrate, gemfibrozil) activate peroxisome proliferator-activated receptor-alpha (PPARα) in the liver and skeletal muscle, increasing lipoprotein lipase activity and reducing VLDL secretion — primarily lowering triglycerides by 25–50% and raising HDL. Bile acid sequestrants (cholestyramine, colesevelam) bind bile acids in the small intestine, preventing their enterohepatic recirculation; the liver compensates by converting more cholesterol into new bile acids, reducing hepatic cholesterol and upregulating LDL receptors. PCSK9 inhibitors (evolocumab, alirocumab) are monoclonal antibodies that inhibit PCSK9 — a protein that targets LDL receptors for degradation; by blocking PCSK9, more LDL receptors are preserved on hepatocyte surfaces to clear LDL from circulation, lowering LDL by up to 60–65%.

Dosing is individualized based on LDL cholesterol targets, cardiovascular risk, and drug tolerability. Common statin doses: rosuvastatin 5–40 mg once daily; atorvastatin 10–80 mg once daily; simvastatin 10–40 mg once daily at night (note: 80 mg dose is no longer recommended due to high myopathy risk); pravastatin 10–40 mg once daily; fluvastatin 20–80 mg daily. Ezetimibe: 10 mg once daily, taken at any time of day with or without food — often combined with a statin in a single combination tablet (atorvastatin/ezetimibe, simvastatin/ezetimibe/Vytorin, rosuvastatin/ezetimibe/Roszet). Fenofibrate: 67–267 mg daily with meals (dose varies by formulation). PCSK9 inhibitors: evolocumab 140 mg subcutaneous injection every 2 weeks or 420 mg monthly; alirocumab 75–150 mg subcutaneous injection every 2 weeks. Inclisiran: 284 mg subcutaneous injection at start, 3 months, then every 6 months. All doses require individualized medical prescription and periodic monitoring of cholesterol levels and safety parameters.

Statins: the most common side effect is muscle-related symptoms (myalgia — aching or weakness) affecting approximately 5–10% of patients; this is frequently dose-dependent and may be dose-limiting. Rare but serious: myopathy (clinically significant muscle inflammation with elevated creatine kinase) in less than 1%, and rhabdomyolysis (severe muscle breakdown with kidney failure) in approximately 1 per 10,000–100,000 patient-years. Mild, usually asymptomatic liver enzyme elevations occur in approximately 1% of patients. New-onset type 2 diabetes is a recognized class effect (approximately 10% relative increase in risk over 5 years) — the cardiovascular benefit vastly outweighs this risk. Statins are contraindicated in pregnancy (teratogenic) and breastfeeding. Ezetimibe: generally very well tolerated; uncommonly causes diarrhea, abdominal discomfort, and joint pain. Fibrates: may cause nausea, stomach upset, gallstones (increased biliary cholesterol secretion), and muscle toxicity — risk of myopathy is substantially elevated when fibrates (especially gemfibrozil) are combined with statins. Bile acid sequestrants: cause gastrointestinal side effects (constipation, bloating, flatulence) in most users and can reduce absorption of fat-soluble vitamins and many drugs — administer other drugs 1 hour before or 4 hours after sequestrants. PCSK9 inhibitors: injection site reactions (redness, pain) in approximately 5%; nasopharyngitis; rare neurocognitive effects (very low incidence, causal relationship uncertain).

Statins are contraindicated in active liver disease, pregnancy (FDA Pregnancy Category X — stop before conception and do not restart until after breastfeeding is complete), and breastfeeding. Report unexplained muscle pain, weakness, tenderness, or dark brown urine (myoglobinuria) to your doctor immediately — do not wait for the next appointment — as this may indicate rhabdomyolysis requiring urgent treatment. Grapefruit juice inhibits CYP3A4-mediated metabolism of atorvastatin and simvastatin — significantly raising blood statin levels and myopathy risk; avoid grapefruit with these statins. Major drug interactions that increase statin levels and myopathy risk: gemfibrozil (avoid with most statins — use fenofibrate instead if a fibrate is needed); cyclosporine (limit statin dose to 10 mg atorvastatin or rosuvastatin); clarithromycin, itraconazole, ketoconazole (CYP3A4 inhibitors); HIV protease inhibitors (ritonavir, lopinavir); colchicine (co-administration increases myopathy risk significantly). Rifampicin substantially reduces statin levels through CYP3A4 induction — may require monitoring. PCSK9 inhibitors as monoclonal antibodies have minimal drug interactions but are expensive and insurance-restricted. Always discuss statin-related muscle symptoms promptly rather than stopping medication without medical advice — the risk of cardiovascular events from stopping statins may exceed the risk from the side effects.